Predictors of adherence among Alzheimer's disease patients receiving oral therapy

Bijan J Borah, Patricia Sacco, Victoria Zarotsky

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objectives: Treatment effectiveness depends upon administering medications as prescribed, and adherence is critical for Alzheimer's disease (AD) patients to receive optimal benefit from therapy. The objective of this study was to investigate factors associated with adherence to AD oral medications. Methods: This retrospective claims analysis identified AD patients who initiated oral AD therapy (rivastigmine, donepezil, galantamine, or memantine) between January 1, 2006 and December 31, 2007 from a large US health plan. Patient baseline characteristics were assessed during the 6-month pre-index period; outcomes were assessed during the 1-year post-index period. Pill burden was measured as a count of unique units of medication/day. Adherence was measured by medication possession ratio (MPR), with MPR 80 defined as adherent. Multivariate logistic regression was used to assess how potential covariates affect adherence probability. Results: A total of 3091 AD patients (36 male; mean age 80 [8.25 SD]) were identified. Only 58 of patients were adherent to oral AD medications. Compared to patients <75 years, patients 86 years were likely to be more adherent (OR1.401, p<0.001). Other factors found to be positively associated with the probability of adherence to AD medications were male gender (OR1.175, p<0.05), overall pill burden (OR1.192, p<0.001), and a lower formulary tier status of the AD medication (OR1.332, p<0.001). Conclusion: Among the several variables assessed, being male, ≥86 years of age, having a greater overall daily pill burden, or using a lower formulary tier AD medication was associated with better adherence to oral AD medication in patients diagnosed with AD. The database had no information on caregiver support, medication management interventions, or use of adherence aids that may have affected adherence in this cohort, yet, a substantial proportion of patients (42) remained non-adherent. A better understanding of the causes of non-adherence is necessary, and methods to improve adherence, such as transdermal medications and educational programs, should be considered.

Original languageEnglish (US)
Pages (from-to)1957-1965
Number of pages9
JournalCurrent Medical Research and Opinion
Volume26
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Alzheimer Disease
Mouth Diseases
Therapeutics
Formularies
Rivastigmine
Insurance Claim Review
Galantamine
Memantine
Caregivers
Logistic Models
Databases
Health

Keywords

  • Alzheimer's disease
  • Donepezil
  • Galantamine
  • Medication adherence
  • Memantine
  • Rivastigmine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Predictors of adherence among Alzheimer's disease patients receiving oral therapy. / Borah, Bijan J; Sacco, Patricia; Zarotsky, Victoria.

In: Current Medical Research and Opinion, Vol. 26, No. 8, 08.2010, p. 1957-1965.

Research output: Contribution to journalArticle

Borah, Bijan J ; Sacco, Patricia ; Zarotsky, Victoria. / Predictors of adherence among Alzheimer's disease patients receiving oral therapy. In: Current Medical Research and Opinion. 2010 ; Vol. 26, No. 8. pp. 1957-1965.
@article{9f75664133bb4c10bc6b08ae5b616127,
title = "Predictors of adherence among Alzheimer's disease patients receiving oral therapy",
abstract = "Objectives: Treatment effectiveness depends upon administering medications as prescribed, and adherence is critical for Alzheimer's disease (AD) patients to receive optimal benefit from therapy. The objective of this study was to investigate factors associated with adherence to AD oral medications. Methods: This retrospective claims analysis identified AD patients who initiated oral AD therapy (rivastigmine, donepezil, galantamine, or memantine) between January 1, 2006 and December 31, 2007 from a large US health plan. Patient baseline characteristics were assessed during the 6-month pre-index period; outcomes were assessed during the 1-year post-index period. Pill burden was measured as a count of unique units of medication/day. Adherence was measured by medication possession ratio (MPR), with MPR 80 defined as adherent. Multivariate logistic regression was used to assess how potential covariates affect adherence probability. Results: A total of 3091 AD patients (36 male; mean age 80 [8.25 SD]) were identified. Only 58 of patients were adherent to oral AD medications. Compared to patients <75 years, patients 86 years were likely to be more adherent (OR1.401, p<0.001). Other factors found to be positively associated with the probability of adherence to AD medications were male gender (OR1.175, p<0.05), overall pill burden (OR1.192, p<0.001), and a lower formulary tier status of the AD medication (OR1.332, p<0.001). Conclusion: Among the several variables assessed, being male, ≥86 years of age, having a greater overall daily pill burden, or using a lower formulary tier AD medication was associated with better adherence to oral AD medication in patients diagnosed with AD. The database had no information on caregiver support, medication management interventions, or use of adherence aids that may have affected adherence in this cohort, yet, a substantial proportion of patients (42) remained non-adherent. A better understanding of the causes of non-adherence is necessary, and methods to improve adherence, such as transdermal medications and educational programs, should be considered.",
keywords = "Alzheimer's disease, Donepezil, Galantamine, Medication adherence, Memantine, Rivastigmine",
author = "Borah, {Bijan J} and Patricia Sacco and Victoria Zarotsky",
year = "2010",
month = "8",
doi = "10.1185/03007995.2010.493788",
language = "English (US)",
volume = "26",
pages = "1957--1965",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Predictors of adherence among Alzheimer's disease patients receiving oral therapy

AU - Borah, Bijan J

AU - Sacco, Patricia

AU - Zarotsky, Victoria

PY - 2010/8

Y1 - 2010/8

N2 - Objectives: Treatment effectiveness depends upon administering medications as prescribed, and adherence is critical for Alzheimer's disease (AD) patients to receive optimal benefit from therapy. The objective of this study was to investigate factors associated with adherence to AD oral medications. Methods: This retrospective claims analysis identified AD patients who initiated oral AD therapy (rivastigmine, donepezil, galantamine, or memantine) between January 1, 2006 and December 31, 2007 from a large US health plan. Patient baseline characteristics were assessed during the 6-month pre-index period; outcomes were assessed during the 1-year post-index period. Pill burden was measured as a count of unique units of medication/day. Adherence was measured by medication possession ratio (MPR), with MPR 80 defined as adherent. Multivariate logistic regression was used to assess how potential covariates affect adherence probability. Results: A total of 3091 AD patients (36 male; mean age 80 [8.25 SD]) were identified. Only 58 of patients were adherent to oral AD medications. Compared to patients <75 years, patients 86 years were likely to be more adherent (OR1.401, p<0.001). Other factors found to be positively associated with the probability of adherence to AD medications were male gender (OR1.175, p<0.05), overall pill burden (OR1.192, p<0.001), and a lower formulary tier status of the AD medication (OR1.332, p<0.001). Conclusion: Among the several variables assessed, being male, ≥86 years of age, having a greater overall daily pill burden, or using a lower formulary tier AD medication was associated with better adherence to oral AD medication in patients diagnosed with AD. The database had no information on caregiver support, medication management interventions, or use of adherence aids that may have affected adherence in this cohort, yet, a substantial proportion of patients (42) remained non-adherent. A better understanding of the causes of non-adherence is necessary, and methods to improve adherence, such as transdermal medications and educational programs, should be considered.

AB - Objectives: Treatment effectiveness depends upon administering medications as prescribed, and adherence is critical for Alzheimer's disease (AD) patients to receive optimal benefit from therapy. The objective of this study was to investigate factors associated with adherence to AD oral medications. Methods: This retrospective claims analysis identified AD patients who initiated oral AD therapy (rivastigmine, donepezil, galantamine, or memantine) between January 1, 2006 and December 31, 2007 from a large US health plan. Patient baseline characteristics were assessed during the 6-month pre-index period; outcomes were assessed during the 1-year post-index period. Pill burden was measured as a count of unique units of medication/day. Adherence was measured by medication possession ratio (MPR), with MPR 80 defined as adherent. Multivariate logistic regression was used to assess how potential covariates affect adherence probability. Results: A total of 3091 AD patients (36 male; mean age 80 [8.25 SD]) were identified. Only 58 of patients were adherent to oral AD medications. Compared to patients <75 years, patients 86 years were likely to be more adherent (OR1.401, p<0.001). Other factors found to be positively associated with the probability of adherence to AD medications were male gender (OR1.175, p<0.05), overall pill burden (OR1.192, p<0.001), and a lower formulary tier status of the AD medication (OR1.332, p<0.001). Conclusion: Among the several variables assessed, being male, ≥86 years of age, having a greater overall daily pill burden, or using a lower formulary tier AD medication was associated with better adherence to oral AD medication in patients diagnosed with AD. The database had no information on caregiver support, medication management interventions, or use of adherence aids that may have affected adherence in this cohort, yet, a substantial proportion of patients (42) remained non-adherent. A better understanding of the causes of non-adherence is necessary, and methods to improve adherence, such as transdermal medications and educational programs, should be considered.

KW - Alzheimer's disease

KW - Donepezil

KW - Galantamine

KW - Medication adherence

KW - Memantine

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=77954717034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954717034&partnerID=8YFLogxK

U2 - 10.1185/03007995.2010.493788

DO - 10.1185/03007995.2010.493788

M3 - Article

VL - 26

SP - 1957

EP - 1965

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 8

ER -